Cantabio Pharmaceuticals Presents Results on Therapeutic Program Targeting DJ-1 Protein
Results of the Cantabio Pharmaceuticals’ therapeutic program targeting the protein DJ-1 as a new therapeutic avenue for Parkinson’s disease…
Articles by Joana Fernandes, PhD
Understanding Parkinson’s Requires a Change in Approach, Experts Say
Increasing treatment success in Parkinson’s requires a change in the way researchers and doctors view and approach this disease, experts…
SPECT Brain Imaging May Not Predict Dopamine Neuron Loss in Parkinson’s
Contrary to current scientific thought, tracking the activity of a protein called dopamine transporter (DAT) may not reflect the loss…
FDA Approves Xadago as Add-on for Parkinson’s Patients on Levodopa/Carbidopa
The U.S. Food and Drug Administration (FDA) has approved Xadago (safinamide) as an add-on therapy to increase the effectiveness of levodopa/carbidopa…
Short Exposure to Air Pollution May Increase Parkinson’s Risk, Korean Study Shows
Even brief exposure to air pollution can increase the risk of Parkinson’s disease and other neurological diseases, concludes a Korean study. The…
Folinic Acid Shows Promise as Parkinson’s Treatment in Fruit Fly Study
Folinic acid, an adjuvant medication for bowel cancer, also may become a potential treatment for early-onset Parkinson’s disease, according to…
Partners in Parkinson’s Opens Education and Support Video Gallery Website
Partners in Parkinson’s has opened a video gallery online to help educate people about the disease and to support services…
Variations in the ‘Ginger Hair’ Gene May Link Melanoma and Parkinson’s Disease
The MC1R gene is associated with ginger hair and fair skin and has been considered a risk factor for melanoma…
Study Highlights Insurance Payment Issues for Off-label Deep Brain Stimulation
Patients who have had deep brain stimulation (DBS) to treat diseases that are not approved for the technique may not be…
Sanofi Launches Phase 2 Trial to Treat PD Patients with Gaucher-Causing Mutation
Sanofi Genzyme is now recruiting participants for a Phase 2 trial to study the safety and efficacy of GZ/SAR402671 for treating Parkinson’s disease…